Bryan Garnier & Co initiates buying coverage of Quantum Genomics with a price target of €13 per share
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC)
a biopharmaceutical company specializing in the development of a new class of drugs that act directly on the brain to treat difficult to treat/resistant hypertension and heart failure, today announces the initiation of its title coverage by Bryan Garnier & Co, pan-European investment bank dedicated to growth companies.
In his introductory study entitled ”
The shape of my heart
», published on October 6, 2022, Bryan Garnier & Co begins monitoring the stock with a recommendation to buy and values the company at
€13 per share, i.e. €450 million, before the announcement of the results of the FRESH phase III study scheduled for November 7, 2022 at the American Heart Association congress.
About Bryan Garnier & Co
A major player in the field of healthcare, Bryan Garnier & Co is an independent European investment bank founded in 1996 which offers a full service focused on growth. It focuses on the main growth sectors of the economy, including technology, healthcare, consumer and business services. Bryan Garnier & Co is a registered, authorized and regulated investment dealer by the FCA in Europe and by FINRA in the
UNITED STATES. Bryan Garnier & Co is headquartered in London with offices in Paris, Munich, Stockholm, Oslo and Reykjavik as well as New York and Palo Alto.
For more information: www.bryangarnier.com
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the mechanism of inhibition of brain Aminopeptidase A (Brain Aminopeptidase A Inhibition or BAPAI). The only company in the world to pursue this innovative approach directly targeting the brain, it relies on more than twenty years of research from the University of Paris-Descartes and the INSERM/CNRS laboratory directed by Dr. Catherine Llorens-Cortès at France secondary school. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant arterial hypertension (around 30% of patients are poorly controlled or fail treatment), and heart failure (one out of two patients diagnosed dies within five years).
Based in Paris, the company is listed on the Euronext Growth market in Paris (FR0011648971 – ALQGC) and registered on the American market OTCQX (symbol: QNNTF).
More information on www.quantum-genomics.com, our Twitter and Linkedin accounts
contacts
|
Quantum Genomics | |
|
Communication building (EUROPE) | |
Financial communication and media | |
|
LifeSci (USA) | |
Mike Tattory |
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
lmlqksablJqVyHFrk5ZumWGUmJlpxWSYlpXLxGeZapmUmmuSymmSl53IZnBnmm5q
– To check this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Other press releases
Full and original press release in PDF format:
https://www.actusnews.com/news/76594-alqgc-bryan-garnier-coverage-french-version.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com